DOCSLIB.ORG

View Final Program

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
View Final Program 142nd ANNUAL MEETING OF THE AMERICAN ANA2017 NEUROLOGICAL ASSOCIATION SAN DIEGO, CA • OCTOBER 15-17, 2017 SHERATON SAN DIEGO HOTEL & MARINA EXPLORE • EXAMINE • INVESTIGATE FINAL PROGRAM OCTOBER 14, 2017 | Pre-Meeting Symposium: Big Science and the BRAIN Initiative 2017.MYANA.org 142nd ANNUAL MEETING OF THE AMERICAN ANA2017 NEUROLOGICAL ASSOCIATION SAN DIEGO, CA • OCTOBER 15 -17, 2017 SHERATON SAN DIEGO HOTEL & MARINA ND Please note some session titles may have changed since this program was printed. Please refer THE 142 ANA to your Mobile app for the most current session updates. ANNUAL MEETING LETTER FROM THE CHAIR 3 Enjoy outstanding scientific SCHEDULE AT A GLANCE 4 symposia covering the latest HOTEL FLOOR PLANS 6 research in the fields of neurology and neuroscience GENERAL INFORMATION 7 while taking the opportunity WIRELESS CONNECTION 8 to network with leaders in the world of academic neurology CONTINUING MEDICAL EDUCATION 8 at the 142nd ANA Annual ANNUAL MEETING MOBILE APP 8 Meeting in San Diego, CA, October 15-17, 2017. PROGRAMS BY DAY 9 SATURDAY OCT 14 9 MEETING LOCATION SUNDAY OCT 15 9 Sheraton San Diego MONDAY OCT 16 17 Hotel & Marina 1380 Harbor Island Drive TUESDAY OCT 17 25 San Diego, California 92101 IN MEMORIAM 28 ONSITE MEETING CONTACTS SPEAKER ABSTRACTS 29 Registration and meeting questions: THANK YOU TO OUR SUPPORTERS & EXHIBITORS 42 [email protected] FUTURE MEETING DATES 42 OR visit the registration desk Bay View Foyer 2017 AWARDEES 43 (located in Marina Tower Lobby Level) ACADEMIC NEUROLOGY REPRESENTATIVES FROM JAPAN 47 Saturday, October 14 2017 ABSTRACT REVIEWERS 48 3:00 PM–7:00 PM BOARD OF DIRECTORS 49 Sunday, October 15 6:00 AM–5:45 PM ANA 2017 COMMITTEES, SUBCOMMITTEES & TASK FORCES 50 Monday, October 16 6:30 AM–5:45 PM Tuesday, October 17 6:30 AM–2:15 PM #ANAMTG2017 ANA 2017 FROM THE CHAIR Dear Colleagues, It is a pleasure to welcome you to the 142nd Annual Meeting of the American Neurological Association (ANA). First, I would like to thank members of the Board of Directors, the Scientific Program Advisory Committee, Dr. James Brewer and the Local Arrangements Subcommittee here in San Diego, and colleagues throughout academic neurology for their hard work and outreach efforts. These efforts have resulted in more than 450 abstract submissions for the 2017 ANA meeting. Laura P.W. Ranum, PhD This year, the ANA Annual Meeting which will be held on October 15 - 17, 2017 in University of Florida Chair, Scientific Program San Diego CA, will offer exceptional scientific talks and posters and an unparalleled Advisory Committee opportunity to connect with colleagues throughout academic neurology. The scientific symposia presented cover a broad spectrum of research areas including precision medicine, antisense oligonucleotide therapies, global neurology, neuronal circuits and behavior, and molecular imaging. The poster sessions are packed with the latest emerging neuroscience. Additionally, the Career Development Sessions, Interactive Lunch Workshops and Special Interest Groups provide opportunities for focused scientific exchange. This meeting also offers an important opportunity for career development at all levels of academic neurology and networking opportunities with leaders in the field. This year, plenary poster-blitz talks, highlighting the scientific contributions of young investigators, have been selected from submitted abstracts. Please be sure to also attend the Pre-Meeting Symposium on Big Science and the BRAIN initiative. The Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative is the most ambitious neuroscience project to date. It is aimed at revolutionizing our understanding of the human brain and seeks to develop technologies that will enable precise monitoring and modulation of neural activity. Now in its third year, a number of tools have been developed that are transforming our understanding of brain circuits. I hope you will take advantage of this evening session as a panel of experts discuss the BRAIN initiative. In addition, it is an honor to highlight that our 2017 Annual Meeting will afford each of us the opportunity to welcome and celebrate our colleagues from the Japanese Society of Neurology. We are thrilled to continue the tradition of recognizing colleagues and collaborators from around the world, as was done with the Italian Neurological Society in 2016, Indian Academy of Neurology in 2015, Mexican Academy of Neurology in 2014, French Société Française de Neurologie in 2013 and Association of British Neurologists in 2012. This coincides with new efforts within the ANA to consider potential programs to extend collaborations in neurological teaching and research with academic neurologists globally. My colleagues on the Board of Directors and all of us on the Scientific Program Advisory Committee are confident that this year’s ANA Annual Meeting will be exceptional. We look forward to seeing you in San Diego! With best regards, OCTOBER 15–17, 2017 | San Diego, CA | #ANAMTG2017 3 (schedule is subject to change) ANA 2017 SCHEDULE AT A GLANCE FRIDAY OCTOBER 13 SUNDAY OCTOBER 15 (CONTINUED) 4:30 PM – 8:15 PM NINDS/ANA Career Development 2. Inflammatory Diseases of the Spinal Cord Symposium | Harbor Island Ballroom 3 Nautilus 1 & 2 By Invitation Only 3. Operative Strategies for Drug-Resistant Focal SATURDAY OCTOBER 14 Epilepsy: Cortical Resection, Responsive Neurostimulation, Deep Brain and Chronic 7:15 AM – 6:45 PM NINDS/ANA Career Development Subthreshold Cortical Stimulation | Nautilus 3 Symposium | Harbor Island Ballroom 3 4. By Invitation Only Meet the Director and Staff of the National Institute of Neurological Disorders and Stroke 3:00 PM – 7:00 PM Registration | Bay View Foyer (NINDS)* | Nautilus 4 & 5 6:00 PM – 7:00 PM PRE-MEETING SYMPOSIUM 5. Meet the Editors I * | Seabreeze Buffet Dinner | Grande Ballroom C 1:15 PM – 3:15 PM PLENARY SESSION 6:45 PM – 7:45 PM NINDS/ANA Career Development Derek Denny-Brown Young Neurological Reception | Harbor Island Ballroom 3 Scholar Symposium | Grande Ballroom AB By Invitation Only 3:30 PM – 5:30 PM Special Interest Group Sessions 7:00 PM – 10:00 PM PRE-MEETING SYMPOSIUM 1. Grande Ballroom C Big Science & the BRAIN Initiative Neuro-Oncology | Grande Ballroom C 2. Neurocritical Care: ICH/IVH: Translational Convergence for Treatment Discovery SUNDAY OCTOBER 15 Nautilus 1 & 2 6:00 AM – 5:45 PM Registration | Bay View Foyer 3. Behavioral Neurology | Nautilus 3 7:00 AM – 9:00 AM Breakfast (Open to All Registrants) 4. Epilepsy: Advances in Electrical Stimulation Bay View & Grande Foyers for Treatment of Epilepsy & Comorbidities Nautilus 4 7:00 AM – 7:30 AM Trainee Breakfast with the ANA Board of Directors* | Nautilus 1 & 2 5. Cerebrovascular Disease | Nautilus 5 (Open to Students, Post-docs, Residents, and Fellows) AUPN SPONSORED 6. Education: Diversity, Inclusion, and Equity in Seabreeze 7:30 AM – 9:00 AM Professional Development Courses Neurology Training | 7. Multiple Sclerosis | Spinnaker Course 1 Students, Residents, Post docs and Fellows Career Level: Early Careers in Academic 8. Movement Disorders | Marina 6 Neurology Nautilus 1 & 2 5:30 PM – 7:00 PM Poster Presentation & Reception I* Course 1 Early- to Mid-Career Level: There is no K in Pavilion Promotion | Nautilus 4 & 5 7:15 PM – 9:15 PM Past Presidents Dinner* | Executive 2 Course 1 AUPN Chair-Career Level: Challenges in By Invitation Only Faculty Compensation | Nautilus 3 MONDAY OCTOBER 16 7:30 AM – 3:30 PM Exhibits Open* | Grande Foyer (Open to All Registrants) 5:45 AM – 7:30 AM SATELLITE SYMPOSIUM: Updates 9:00 AM – 9:15 AM Coffee Break | Bay View & Grande Foyers SPONSORED in Diagnosing and Treating Alzheimer BY MEDSCAPE Disease | Grande Ballroom C 9:15 AM – 11:15 AM PLENARY SESSION Linking Circuits to Behavior: 6:30 AM – 5:45 PM Registration | Bay View & Grande Foyers Promise & Perils | Grande Ballroom AB 7:00 AM – 9:00 AM Breakfast (Open to All Registrants) 11:00 AM – 7:00 PM Poster Viewing* Bay View & Grande Foyers Poster presenters and judges will be in 7:30 AM – 9:00 AM Professional Development Courses attendance from 5:30 PM – 7:00 PM | Pavilion 11:15 AM – 11:45 AM New Member Meet and Greet* Course 2 Students, Residents, Post-docs and Fellows with ANA Past Presidents & Current Leadership Career Level: The Many Faces of Academic Spinnaker Global Neurology | Nautilus 1 & 2 Course 2 Early- to Mid-Career Level: Roads Less Traveled- 11:45 AM – 1:00 PM Lunch | Bay View & Grande Foyers Creative Careers Off the Beaten Track Nautilus 4 & 5 11:45 AM – 1:00 PM Interactive Lunch Workshops Course 2 AUPN Chair-Career Level: Politics for 1. Management of Severe Pediatric Traumatic Neurology Chairs | Nautilus 3 Brain Injury: What is the Evidence? Grande Ballroom C 7:30 AM – 3:30 PM Exhibits Open* | Grande Foyer (Open to All Registrants) 4 2017.MYANA.ORG | 142nd Annual Meeting of the American Neurological Association | FINAL PROGRAM | * This session is not available for AMA PRA Category 1 Credit(s)™ ANA 2017 SCHEDULE AT A GLANCE MONDAY OCTOBER 16 (CONTINUED) MONDAY OCTOBER 16 (CONTINUED) 9:00 AM – 9:15 AM Coffee Break | Bay View & Grande Foyers 5:30 PM – 7:00 PM Poster Presentation & Reception II* Pavilion 9:15 AM – 11:15 AM PLENARY SESSION PRESIDENTIAL SYMPOSIUM 7:30 PM – 9:00 PM President's Reception* | Bay View Lawn Translational Neuroscience Research to Improve Outcomes for the 'Bottom Billion' TUESDAY OCTOBER 17 Grande Ballroom AB 6:30 AM – 2:15 PM Registration | Bay View Foyer 11:00 AM – 7:00 PM Poster Viewing* 7:00 AM – 8:30 AM Poster presenters and judges will be in Professional Development Courses attendance from 5:30 PM – 7:00 PM | Pavilion Please note early start time for Tuesday sessions 11:15 AM – 11:45 AM Executive Session of Membership* Course 3 Students, Residents, Post-docs and Fellows All members are encouraged to attend Career Level: Preparing for Your First Faculty Grande Ballroom AB Position—A Workshop for New Academic Neurologists Nautilus 1 & 2 11:45 AM – 1:00 PM Lunch | & Grande Foyers Course 3 Early- to Mid-Career Level: The View from 11:45 AM – 1:00 PM Interactive Lunch Workshops the NIH and Successful Grant Writing 1.
Load more

Recommended publications
  • Huda Y. Zoghbi, MD, Howard Hughes Medical Institute, Jan and Dan Duncan Neurological Research Institute at Texas Children’S Hospital and Baylor College of Medicine
    Investigator Spotlight: Huda Y. Zoghbi, MD, Howard Hughes Medical Institute, Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital and Baylor College of Medicine It is hard to believe that the 7th World Rett Syndrome Congress has come and gone with great success! Now with summer upon us, IRSF continues to move the spotlight to the committed scientists who have made the World Congress an impressive, high quality meeting with outstanding presentations and discussions. This month we are honored to focus on Dr. Huda Zoghbi who had co-chaired the Basic Research Symposium at the World Congress along with Dr. Gail Mandel. Together, they had produced an exciting lineup of speakers who were encouraged to present new, unpublished data in an effort to foster new ideas that will help chart the course for Rett syndrome research. Dr. Zoghbi is a Howard Hughes Medical Institute (HHMI) Investigator, the Director of the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, and Professor of the Baylor College of Medicine in Houston, TX. She received her medical degree from Meharry Medical College and completed residency training in pediatrics and neurology at Baylor College of Medicine where she encountered her first Rett syndrome patient in 1983. Dr. Zoghbi was inspired to receive additional research training in the area molecular genetics and upon completion she joined the faculty of Baylor College of Medicine. In 1999, Dr. Zoghbi and collaborators including research fellow Ruthie Amir made a major breakthrough for Rett syndrome. They had discovered that mutations in MECP2, the gene encoding methyl-CpG-binding protein 2, causes Rett syndrome.
    [Show full text]
  • UC San Diego UC San Diego Electronic Theses and Dissertations
    UC San Diego UC San Diego Electronic Theses and Dissertations Title Spinocerebellar Ataxia Type 7 is Characterized by Defects in Mitochondrial and Metabolic Function Permalink https://escholarship.org/uc/item/02b7m809 Author Ward, Jacqueline Marie Publication Date 2016 Supplemental Material https://escholarship.org/uc/item/02b7m809#supplemental Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California UNIVERSITY OF CALIFORNIA, SAN DIEGO Spinocerebellar Ataxia Type 7 is Characterized by Defects in Mitochondrial and Metabolic Function A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Biomedical Sciences by Jacqueline Marie Ward Committee in charge: Professor Albert La Spada, Chair Professor Eric Bennett Professor Lawrence Goldstein Professor Alysson Muotri Professor Miles Wilkinson 2016 Copyright Jacqueline Marie Ward, 2016 All rights reserved The Dissertation of Jacqueline Marie Ward is approved, and it is acceptable in quality and form for publication on microfilm and electronically: Chair University of California, San Diego 2016 iii DEDICATION This work is dedicated to my grandfather, Dr. Wayne Ward, the kindest person I’ve ever known. His memory inspires me to be a better person daily. iv TABLE OF CONTENTS SIGNATURE PAGE .......................................................................................... iii DEDICATION ..................................................................................................
    [Show full text]
  • Missing Link Connects Diabetes and Alzheimer's Disease
    Missing Link Connects Diabetes and Alzheimer’s Disease A gene called PGC-1! is associated with the onset of Type 2 diabetes, associated with dementia and but it has shown to decrease in Alzheimer’s disease dementia cases. an accumulation in the brain of The gene is a potential target for regulating glucose, according to an abnormal protein known as new research led by Giulio Maria Pasinetti, MD, PhD, the Aidekman "-amyloid. This abnormal protein Family Professor in Neurology, and Professor of Psychiatry and causes plaque buildup in the Geriatrics and Adult Development. The study was recently published brain, which is linked to cognitive in Archives of Neurology. deterioration in Alzheimer’s disease. The PGC-1! gene, which plays an important role in regulating We may be able to link a gene—whose glucose metabolism, is considered a potential target for treating alteration may lead to diabetes—to a Type 2 diabetes. Giulio Maria Pasinetti, MD, PhD mechanism that would promote conditions Using a mouse model of associated with Alzheimer’s disease. Alzheimer’s disease, Dr. Pasinetti and his team also found that promoting PGC-1! content in brain cells reduces the hyperglycemic- — GIULIO MARIA PASINETTI, MD, PHD mediated production of "-amyloid. The findings could help researchers identify potential pharmacological treatments that might promote PGC-1! expression Previous studies suggest that Type 2 diabetes is a risk factor for in the brain cells of Alzheimer’s patients. “We need to discover Alzheimer’s disease. The relationship between the two conditions is new therapeutic approaches for Alzheimer’s disease by looking at “a fascinating new area of research,” says Dr.
    [Show full text]
  • Program Book
    PARKINSON’SDISEASE2014 ADVANCING RESEARCH, IMPROVING LIVES PROGRAM MATERIALS Sponsored by: January 6 – 7, 2014 Natcher Conference Center National Institutes of Health Bethesda, MD About our cover: The program cover image is a stylized version of the Parkinson’s Disease Motor-Related Pattern (PDRP), an abnormal pattern of regional brain function observed in MRI studies which shows increased metabolism indicated by red in some brain regions (pallidothalamic, pontine, and motor cortical areas), and decreased metabolism indicated by blue in others (associated lateral premotor and posterior parietal areas). Original image used with permission of David Eidelberg, M.D. For further information see: Hirano et al., Journal of Neuroscience 28 (16): 4201-4209. Welcome Message from Dr. Story C. Landis Welcome to the National Institute of Neurological Disorders and Stroke (NINDS) conference, “Parkinson’s Disease 2014: Advancing Research, Improving Lives.” Remarkable new discoveries and technological advances are rapidly changing the way we study the biological mechanisms of Parkinson’s disease, identify paths to improved treatments, and design effective clinical trials. Elucidating mechanisms and developing and testing effective interventions require a diverse set of approaches and perspectives. The NINDS has organized this conference with the primary goal of seeking consensus on, and prioritizing, research recommendations spanning clinical, translational, and basic Parkinson’s disease research that we support. We have assembled a stellar and dedicated group of session chairs and panelists who have worked collaboratively to identify emerging research opportunities in Parkinson’s research. While we have divided our working groups into three main research areas, we expect each will inform the others over the course of the next two days, and we look forward to both complementary and unique perspectives.
    [Show full text]
  • Cytokine Gene Expression As a Function of the Clinical Progression of Alzheimer Disease Dementia
    ORIGINAL CONTRIBUTION Cytokine Gene Expression as a Function of the Clinical Progression of Alzheimer Disease Dementia James D. Luterman, PhD; Vahram Haroutunian, PhD; Shrishailam Yemul, PhD; Lap Ho, PhD; Dushyant Purohit, MD; Paul S. Aisen, MD; Richard Mohs, MD; Giulio Maria Pasinetti, MD, PhD Background: Inflammatory cytokines have been linked gyrus (P,.01). When stratified by the Consortium to to Alzheimer disease (AD) neurodegeneration, but little Establish a Registry for Alzheimer’s Disease (CERAD) is known about the temporal control of their expression neuropathological criteria, IL-6 mRNA expression in in relationship to clinical measurements of AD demen- both the entorhinal cortex (P,.05) and superior tem- tia progression. poral gyrus (P,.01) correlated with the level of neuro- fibrillary tangles but not neuritic plaques. However, in Design and Main Outcome Measures: We mea- the entorhinal cortex, TGF-b1 mRNA did not correlate sured inflammatory cytokine messenger RNA (mRNA) with the level of either neurofibrillary tangles or neu- expression in postmortem brain specimens of elderly sub- ritic plaques. Interestingly, in the superior temporal jects at different clinical stages of dementia and neuro- gyrus, TGF-b1 mRNA expression negatively correlated pathological dysfunction. with neurofibrillary tangles (P,.01) and showed no relationship to the pathological features of neuritic Setting and Patients: Postmortem study of nursing plaques. home patients. Conclusions: The data are consistent with the hypoth- Results: In brains of cognitively normal control sub- esis that cytokine expression may differentially contrib- jects, higher interleukin 6 (IL-6) and transforming ute to the vulnerability of independent cortical regions growth factor b1 (TGF-b1) mRNA expression was during the clinical progression of AD and suggest that observed in the entorhinal cortex and superior temporal an inflammatory cytokine response to the pathological gyrus compared with the occipital cortex.
    [Show full text]
  • Huda Zoghbi: Taking Genetic Inquiry to the Next Level
    Spectrum | Autism Research News https://www.spectrumnews.org NEWS, PROFILES Huda Zoghbi: Taking genetic inquiry to the next level BY RACHEL ZAMZOW 25 JUNE 2021 Listen to this story: Most mornings, Huda Zoghbi, 67, climbs a glass-encased, curling staircase to reach her lab on the top and 13th floor of the Jan and Dan Duncan Neurological Research Institute in Houston, Texas. The twisting glass tower, which she designed with a team of architects, echoes the double helix of DNA — a structure that has been central to her career-long quest to uncover genes underlying neurological conditions. As the institute’s director — and as a scientist— she is known for going beyond the standard job description. Genetics researchers often cast a wide net and sequence thousands of genes at a time. But in her prolific career, Zoghbi has focused on a handful of genes, methodically building up an understanding of their function one careful step at a time. Thanks to that approach, Zoghbi has made a number of landmark discoveries, including identifying the genetic roots of Rett syndrome, an autism-related condition that primarily affects girls, as well as the genetic mutations that spur spinocerebellar ataxia, a degenerative motor condition. She has authored more than 350 journal articles. Her accomplishments have earned her almost every major biology and neuroscience research award, including the prestigious Breakthrough Prize in 2017 and the Brain Prize in 2020. “She’s clearly the international leader in the field,” said the late Stephen Warren, professor of human genetics at Emory University in Atlanta, Georgia. Zoghbi never set out to lead a large research center, she says — her heart is in the lab.
    [Show full text]
  • 2016 Joint Meeting Program
    April 15 – 17, 2016 Fairmont Chicago Millennium Park • Chicago, Illinois The AAP/ASCI/APSA conference is jointly provided by Boston University School of Medicine and AAP/ASCI/APSA. Meeting Program and Abstracts www.jointmeeting.org www.jointmeeting.org Special Events at the 2016 AAP/ASCI/APSA Joint Meeting Friday, April 15 Saturday, April 16 ASCI President’s Reception ASCI Food and Science Evening 6:15 – 7:15 p.m. 6:30 – 9:00 p.m. Gold Room The Mid-America Club, Aon Center ASCI Dinner & New Member AAP Member Banquet Induction Ceremony (Ticketed guests only) (Ticketed guests only) 7:00 – 10:00 p.m. 7:30 – 9:45 p.m. Imperial Ballroom, Level B2 Rouge, Lobby Level How to Solve a Scientific Puzzle: Speaker: Clara D. Bloomfield, MD Clues from Stockholm and Broadway The Ohio State University Comprehensive Cancer Center Speaker: Joe Goldstein, MD APSA Welcome Reception & University of Texas Southwestern Medical Center at Dallas Presidential Address APSA Dinner (Ticketed guests only) 9:00 p.m. – Midnight Signature Room, 360 Chicago, 7:30 – 9:00 p.m. John Hancock Center (off-site) Rouge, Lobby Level Speaker: Daniel DelloStritto, APSA President Finding One’s Scientific Niche: Musings from a Clinical Neuroscientist Speaker: Helen Mayberg, MD, Emory University Dessert Reception (open to all attendees) 10:00 p.m. – Midnight Imperial Foyer, Level B2 Sunday, April 17 APSA Future of Medicine and www.jointmeeting.org Residency Luncheon Noon – 2:00 p.m. Rouge, Lobby Level 2 www.jointmeeting.org Program Contents General Program Information 4 Continuing Medical Education Information 5 Faculty and Speaker Disclosures 7 Scientific Program Schedule 9 Speaker Biographies 16 Call for Nominations: 2017 Harrington Prize for Innovation in Medicine 26 AAP/ASCI/APSA Joint Meeting Faculty 27 Award Recipients 29 Call for Nominations: 2017 Harrington Scholar-Innovator Award 31 Call for Nominations: George M.
    [Show full text]
  • Annual Report Fy 2018 Human Frontier Science Program Organization
    APRIL 2017 APRIL 2018 — MARCH 2019 ANNUAL REPORT FY 2018 HUMAN FRONTIER SCIENCE PROGRAM ORGANIZATION The Human Frontier Science Program Organization (HFSPO) is unique, supporting international collaboration to undertake innovative, risky, basic research at the frontier of the life sciences. Special emphasis is given to the support and training of independent young investigators, beginning at the postdoctoral level. The Program is implemented by an international organisation, supported financially by Australia, Canada, France, Germany, India, Italy, Japan, the Republic of Korea, New Zealand, Norway, Singapore, Switzerland, the United Kingdom of Great Britain and Nothern Ireland, the United States of America, and the European Commission. Since 1990, over 7000 researchers from more than 70 countries have been supported. Of these, 28 HFSP awardees have gone on to receive the Nobel Prize. 2 The following documents are available on the HFSP website www.hfsp.org: Joint Communiqués (Tokyo 1992, Washington 1997, Berlin 2002, Bern 2004, Ottawa 2007, Canberra 2010, Brussels 2013, London 2016): https://www.hfsp.org/about/governance/membership Statutes of the International Human Frontier Science Program Organization: https://www.hfsp.org/about/governance/hfspo-statutes Guidelines for the participation of new members in HFSPO: https://www.hfsp.org/about/governance/membership General reviews of the HFSP (1996, 2001, 2006-2007, 2010, 2018): https://www.hfsp.org/about/strategy/reviews Updated and previous lists of awards, including titles and abstracts:
    [Show full text]
  • An Eye to the Future Advances in Imaging Are Accelerating the Pace of Biological Discovery
    fall 2007 An Eye to the Future Advances in imaging are accelerating the pace of biological discovery. A new cellular imaging initiative at the University has researchers seeing small and thinking big. story on page 8 p r o f i l e s college News c l a s s N o t e s from the dean Where curiosity- and solution- driven science meet ome scientists are driven by a curiosity to under- As a curiosity-driven college, it’s CBS’ job to keep S stand how life works—from molecules to eco- adding to the foundation of knowledge that supports systems—and to add to the world’s collective body of translational and solution-driven science in other col- knowledge. Others are searching for a puzzle piece leges. As such, we are the stewards of the foundational that may yield a better way to treat cancer, produce disciplines in the biological sciences: biochemistry, food or create renewable forms of energy. molecular biology, genetics, cell biology and develop- ment, ecology, plant biology, etc. Both are essential, and there is plenty of overlap Robert Elde, Dean between the two. Curiosity-driven research often turns In order to keep fueling translational and solution- up a bit of information that has immediate applications driven research, we need to infuse foundational disci- in medicine, agriculture or engineering. By the same plines with new technologies and other opportunities token, solution-driven research can add to knowledge. as science evolves. And some scientists travel between these two worlds. Fall 07 Vol. 5 No. 3 Cellular imaging, the subject of our cover story, is one As a whole, College of Biological Sciences faculty of those opportunities.
    [Show full text]
  • Obesity & Weight Management
    Giulio Maria Pasinetti, J Obes Wt Loss Ther 2012, 2:9 http://dx.doi.org/10.4172/2165-7904.S1.003 International Conference and Exhibition on Obesity & Weight Management December 3-5, 2012 DoubleTree by Hilton Philadelphia, USA HDAC IIa-specific inhibitors as a potential novel therapy for type 2 diabetes-mediated cognitive deterioration in alzheimer’s disease Giulio Maria Pasinetti Mount Sinai School of Medicine, USA ur laboratory recently demonstrated that epigenetic chromatin modifications associated with type-2 diabetes (T2DM) may Oplay a role in brain pathophysiology in neurodegenerative disorders. We previously discovered that there are significant changes in the expression of select chromatin modification enzymes, such as histone deacetylases (HDACs), in the brains of T2DM subjects compared to control subjects, and that these changes coincide with altered expression of proteins involved in synaptic function, such as PSD95 and synaptophysin. We hypothesized that T2DM may induce epigenetic modifications associated with increased susceptibility to Alzheimer’s disease (AD)-type neurodegeneration. Using a mouse model of diet- induced T2DM, we found that, similar to humans, T2DM mice showed differential expression of epigenetic-modifying enzymes in the brain compared to controls. In particular, we found significant up-regulation of HDAC class IIa, including HDACs 4, 5, and 9, in the brains of diabetic mice. These alterations coincided with increased susceptibility to oligomeric Aβ (oAβ) induced synaptic toxicity and oAβ-induced synaptic dysfunction, as assessed by long term potentiation (LTP). Most interestingly, we found that inhibition of class IIa HDACs using an HDAC IIa-specific inhibitor, MC1568, increased transcription levels of PSD95 and synaptophysin in primary neuron cultures from C57Bl6/J mice and prevented LTP deficits found in old-T2DM mouse ex vivo hippocampal slices.
    [Show full text]
  • Jacob and Louise Gabbay Award in Biotechnology and Medicine in 2016 to Honor Jacob’S Wife, Louise Gabbay, Who Was Instrumental in Founding the Award
    JACOB AND LOUISE JACOB AND LOUISE GABBAY AWARDGABBAY AWARD IN BIOTECHNOLOGY IN BIOTECHNOLOGYAND MEDICINE AND MEDICINE PRESENTATION CEREMONY 19th THURSDAY, SEPTEMBER 29, 2016 Annual WALTHAM, MASS. BRANDEIS UNIVERSITY Early in 1998, the trustees of the Jacob and Louise Gabbay Foundation decided to establish a major new award in basic and applied biomedical sciences. The foundation felt that existing scientific awards tended to honor people who were already well-recognized or to focus on work that had its primary impact in traditional basic research fields. Yet the history of science suggests that most scientific revolu- tions are sparked by advances in practical areas such as instrumentation and techniques or through entrepreneurial endeavors. The foundation therefore created the Jacob Heskel Gabbay Award in Biotechnology and Medicine to recognize, as early as possible in their careers, scientists in academia, medicine or industry whose work had both outstanding scientific content and significant practical consequences in the biomedical sciences. The award was renamed the Jacob and Louise Gabbay Award in Biotechnology and Medicine in 2016 to honor Jacob’s wife, Louise Gabbay, who was instrumental in founding the award. Because of their long association with Brandeis University, the trustees of the foundation asked the Rosenstiel Basic Medical Sciences Research Center at Brandeis to administer the award. The award, given annually, consists of a $15,000 cash prize (to be shared in the case of multiple winners) and a medallion. The honorees travel to Brandeis University each fall to present lectures on their work and attend a dinner at which the formal commendation takes place. This year, a committee of distinguished scientists selected Jeffery Kelly of the Scripps Research Institute for his profound and paradigm-shifting contri- butions to our understanding of protein-folding mechanisms and protein-folding diseases.
    [Show full text]
  • The BBVA Foundation Frontiers of Knowledge Award Goes to the Architects of Optogenetics, Which Uses Light to Probe and Modulate the Workings of the Brain
    Three neuroscientists win the Biomedicine award The BBVA Foundation Frontiers of Knowledge Award goes to the architects of optogenetics, which uses light to probe and modulate the workings of the brain Edward Boyden, Karl Deisseroth and Gero Miesenböck developed and refined a technique that employs light to activate and inactivate proteins in the brain cells, making it possible to modulate their activity with unprecedented precision Optogenetics is now a widely used tool being applied to elucidate functions like sleep, appetite and movement or reward circuits in addiction The awardees all emphasize the basic knowledge underpinning the technique, which, they say, will eventually yield new opportunities in the clinic Madrid, January 26, 2016.- The BBVA Foundation Frontiers of Knowledge Award in Biomedicine goes in this eighth edition to neuroscientists Edward Boyden, Karl Deisseroth and Gero Miesenböck for the development of optogenetics, a method to study brain function with unprecedented resolution. In a bare five years, thousands of groups the world over have begun using optogenetics to investigate functions like sleep, appetite, decision-making, temporal perception or the creation of memories, and elucidate the mechanisms of conditions such as epilepsy, Parkinson’s, depression and certain forms of blindness. The beauty of optogenetics is that it allows the selective control of neural activity simply by applying light of the right wavelength. Before, the most widely used methods to study the living brain could modulate the activity of hundreds of thousands of neurons, but with little selectivity. With optogenetics, it is possible to act exclusively on neurons treated previously with light-sensitive proteins, according to the behavior being tested.
    [Show full text]